[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100308124":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":43,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":10,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":10,"maxAge":10,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Takeda","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"GOS Participants",null,"GOS is a disease specific registry open to all Gaucher patients irrespective of treatment status or type of treatment",[13],{"name":14,"affiliation":15,"role":16},"Shire Study Physician","Shire","STUDY_DIRECTOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Shire Contact","CONTACT","+1 866 842 5335","ClinicalTransparency@shire.com",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Central Contact","RECRUITING","Lexington","Massachusetts","02421","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-71.2245,42.44732,{"lat":36,"lon":35},[39,41],{"name":40,"role":20,"phone":10,"phoneExt":10,"email":22},"Shire Central Contact",{"name":25,"role":42,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100308124","gaucher-disease-outcome-survey-gos-100308124",false,"NCT03291223","Gaucher Disease Outcome Survey (GOS)","Inclusion Criteria:\n\n* Patients of any age or gender with confirmed diagnosis (biochemical and\u002For genetic) of Gaucher disease\n* Signed and dated written informed consent from the patient or, for patients aged \\\u003C18 years (\\\u003C16 years in the United Kingdom \\[UK\\]), their parent and\u002For legally authorized representatives (LAR), and assent of the minor where applicable. Legally authorized representatives are also applicable for cognitively impaired patients.\n\nExclusion Criteria:\n\n\\- Patients currently enrolled in ongoing blinded clinical trials (drugs or devices; includes all blinded trials)","ALL",{"count":53,"type":54},1257,"ESTIMATED","6 Months","OBSERVATIONAL","The Gaucher Outcomes Survey (GOS) is an ongoing observational, international, multi-center, long-term Registry of Patients with Gaucher Disease irrespective of their treatment status or type of treatment received. No experimental intervention is involved. Patients undergo clinical assessments and receive care as determined by the patients' treating physician.\n\nThe objectives of the registry include to evaluate the safety and long-term effectiveness of velaglucerase alfa, to characterize patients receiving velaglucerase alfa or other Gaucher Disease-specific treatments, to gain a better understanding of the natural history of GD and to serve as a database for evidence-based management of Gaucher Disease over time in real-life clinical practice.",[59],"Gaucher Disease","2026-05-11",{"date":62,"type":63},"2026-05-14","ACTUAL",{"date":65,"type":63},"2010-12-29",{"date":67,"type":54},"2026-09-30",{"name":15,"class":6},1]